1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 7 2 Introduction 8 2.1 Pneumonia Report Coverage 8 2.2 Community Acquired Pneumonia - Overview 8 2.3 Hospital Acquired Pneumonia (HAP) - Overview 8 2.4 Ventilator Associated Pneumonia (VAP) - Overview 8 3 Therapeutics Development 9 3.1 Community Acquired Pneumonia 9 3.2 Hospital Acquired Pneumonia (HAP) 13 3.3 Ventilator Associated Pneumonia (VAP) 19 4 Therapeutics Assessment 24 4.1 Community Acquired Pneumonia 24 4.2 Hospital Acquired Pneumonia (HAP) 30 4.3 Ventilator Associated Pneumonia (VAP) 37 5 Companies Involved in Therapeutics Development 44 5.1 Community Acquired Pneumonia 44 5.2 Hospital Acquired Pneumonia (HAP) 51 5.3 Ventilator Associated Pneumonia (VAP) 64 6 Dormant Projects 75 6.1 Community Acquired Pneumonia 75 6.2 Hospital Acquired Pneumonia (HAP) 76 6.3 Ventilator Associated Pneumonia (VAP) 77 7 Discontinued Products 78 7.1 Community Acquired Pneumonia 78 7.2 Hospital Acquired Pneumonia (HAP) 78 7.3 Ventilator Associated Pneumonia (VAP) 79 8 Product Development Milestones 80 8.1 Community Acquired Pneumonia 80 8.2 Hospital Acquired Pneumonia (HAP) 95 8.3 Ventilator Associated Pneumonia (VAP) 109 9 Appendix 122 9.1 Methodology 122 9.2 Coverage 122 9.3 Secondary Research 122 9.4 Primary Research 122 9.5 Expert Panel Validation 122 9.6 Contact Us 123 9.7 Disclaimer 123

1.1 List of Tables Table 1: Number of Products under Development for Community Acquired Pneumonia 9 Table 2: Number of Products under Development by Companies Community Acquired Pneumonia 11 Table 3: Products under Development by Companies Community Acquired Pneumonia 12 Table 4: Number of Products under Development for Hospital Acquired Pneumonia (HAP) 13 Table 5: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP) 15 Table 6: Products under Development by Companies Hospital Acquired Pneumonia (HAP) 16 Table 7: Number of Products under Development for Ventilator Associated Pneumonia (VAP) 19 Table 8: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP) 21 Table 9: Products under Development by Companies Ventilator Associated Pneumonia (VAP) 22 Table 10: Number of Products by Stage and Target Community Acquired Pneumonia 25 Table 11: Number of Products by Stage and Mechanism of Action Community Acquired Pneumonia 26 Table 12: Number of Products by Stage and Route of Administration Community Acquired Pneumonia 28 Table 13: Number of Products by Stage and Molecule Type Community Acquired Pneumonia 29 Table 14: Number of Products by Stage and Target Hospital Acquired Pneumonia (HAP) 31 Table 15: Number of Products by Stage and Mechanism of Action Hospital Acquired Pneumonia (HAP) 33 Table 16: Number of Products by Stage and Route of Administration Hospital Acquired Pneumonia (HAP) 35 Table 17: Number of Products by Stage and Molecule Type Hospital Acquired Pneumonia (HAP) 36 Table 18: Number of Products by Stage and Target Ventilator Associated Pneumonia (VAP) 38 Table 19: Number of Products by Stage and Mechanism of Action Ventilator Associated Pneumonia (VAP) 40 Table 20: Number of Products by Stage and Route of Administration Ventilator Associated Pneumonia (VAP) 42 Table 21: Number of Products by Stage and Molecule Type Ventilator Associated Pneumonia (VAP) 43 Table 22: Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC 44 Table 23: Community Acquired Pneumonia - Pipeline by Biotest AG 44 Table 24: Community Acquired Pneumonia - Pipeline by InflaRx GmbH 45 Table 25: Community Acquired Pneumonia - Pipeline by ioGenetics Inc 45 Table 26: Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co Ltd 46 Table 27: Community Acquired Pneumonia - Pipeline by Melinta Therapeutics Inc 46 Table 28: Community Acquired Pneumonia - Pipeline by Merck & Co Inc 47 Table 29: Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG 47 Table 30: Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals Inc 48 Table 31: Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co Ltd 48 Table 32: Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Ltd 49 Table 33: Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc 50 Table 34: Community Acquired Pneumonia - Pipeline by TiGenix NV 50 Table 35: Community Acquired Pneumonia - Pipeline by Wockhardt Ltd 51 Table 36: Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc 51 Table 37: Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS 52 Table 38: Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC 52 Table 39: Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc 53 Table 40: Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG 54 Table 41: Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp 54 Table 42: Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd 55 Table 43: Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd 55 Table 44: Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc 56 Table 45: Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC 56 Table 46: Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd 57 Table 47: Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc 57 Table 48: Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc 58 Table 49: Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc 59 Table 50: Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG 59 Table 51: Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd 60 Table 52: Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH 60 Table 53: Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd 61 Table 54: Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc 61 Table 55: Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company 62 Table 56: Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc 62 Table 57: Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd 63 Table 58: Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc 63 Table 59: Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc 64 Table 60: Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS 64 Table 61: Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC 65 Table 62: Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc 66 Table 63: Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG 66 Table 64: Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp 67 Table 65: Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd 67 Table 66: Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd 68 Table 67: Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc 68 Table 68: Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC 69 Table 69: Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd 69 Table 70: Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc 70 Table 71: Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc 70 Table 72: Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG 70 Table 73: Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd 71 Table 74: Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd 71 Table 75: Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc 72 Table 76: Ventilator Associated Pneumonia (VAP) - Pipeline by The Medicines Company 73 Table 77: Ventilator Associated Pneumonia (VAP) - Pipeline by Theravance Biopharma Inc 73 Table 78: Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd 74 Table 79: Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics Inc 74 Table 80: Community Acquired Pneumonia - Dormant Projects 75 Table 81: Hospital Acquired Pneumonia (HAP) - Dormant Projects 76 Table 82: Ventilator Associated Pneumonia (VAP) - Dormant Projects 77 Table 83: Community Acquired Pneumonia - Discontinued Products 78 Table 84: Hospital Acquired Pneumonia (HAP) - Discontinued Products 78 Table 85: Ventilator Associated Pneumonia (VAP) - Discontinued Products 79 1.2 List of Figures Figure 1: Number of Products under Development for Community Acquired Pneumonia 9 Figure 2: Number of Products under Development by Companies Community Acquired Pneumonia 10 Figure 3: Number of Products under Development for Hospital Acquired Pneumonia (HAP) 13 Figure 4: Number of Products under Development by Companies Hospital Acquired Pneumonia (HAP) 14 Figure 5: Number of Products under Development for Ventilator Associated Pneumonia (VAP) 19 Figure 6: Number of Products under Development by Companies Ventilator Associated Pneumonia (VAP) 20 Figure 7: Number of Products by Targets Community Acquired Pneumonia 24 Figure 8: Number of Products by Stage and Targets Community Acquired Pneumonia 24 Figure 9: Number of Products by Mechanism of Actions Community Acquired Pneumonia 25 Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions Community Acquired Pneumonia 26 Figure 11: Number of Products by Routes of Administration Community Acquired Pneumonia 27 Figure 12: Number of Products by Stage and Routes of Administration Community Acquired Pneumonia 27 Figure 13: Number of Products by Molecule Types Community Acquired Pneumonia 28 Figure 14: Number of Products by Stage and Molecule Types Community Acquired Pneumonia 29 Figure 15: Number of Products by Top 10 Targets Hospital Acquired Pneumonia (HAP) 30 Figure 16: Number of Products by Stage and Top 10 Targets Hospital Acquired Pneumonia (HAP) 30 Figure 17: Number of Products by Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP) 32 Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions Hospital Acquired Pneumonia (HAP) 32 Figure 19: Number of Products by Routes of Administration Hospital Acquired Pneumonia (HAP) 34 Figure 20: Number of Products by Stage and Routes of Administration Hospital Acquired Pneumonia (HAP) 34 Figure 21: Number of Products by Molecule Types Hospital Acquired Pneumonia (HAP) 35 Figure 22: Number of Products by Stage and Molecule Types Hospital Acquired Pneumonia (HAP) 36 Figure 23: Number of Products by Top 10 Targets Ventilator Associated Pneumonia (VAP) 37 Figure 24: Number of Products by Stage and Top 10 Targets Ventilator Associated Pneumonia (VAP) 37 Figure 25: Number of Products by Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP) 39 Figure 26: Number of Products by Stage and Top 10 Mechanism of Actions Ventilator Associated Pneumonia (VAP) 39 Figure 27: Number of Products by Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP) 41 Figure 28: Number of Products by Stage and Top 10 Routes of Administration Ventilator Associated Pneumonia (VAP) 41 Figure 29: Number of Products by Molecule Types Ventilator Associated Pneumonia (VAP) 42 Figure 30: Number of Products by Stage and Molecule Types Ventilator Associated Pneumonia (VAP) 43